Parkinson's Disease Treatment for Walking and Balance This patient was in between diagnoses of Parkinson's Disease and Spino Cerebellar ataxia. The medication for Parkinson's disease was not helping her. Within twenty minutes I diagnosed the directional balance problems with Balance-Based Torso-Weighting and strategically weighted her. She received a BalanceWear OW200 orthotic. I will be discussing our current research in Parkinson's Disease.From:motiontherapeuticsViews:1600 2ratingsTime:01:59More inScience Technology Read the original here: Parkinson's Disease Treatment for Walking and Balance - Video … Continue reading →

Ataxia treatment From:motiontherapeuticsViews:1904 3ratingsTime:03:55More inScience Technology View post: Ataxia treatment - Video … Continue reading →

EXTON, Pa., Oct. 25, 2012 /PRNewswire/ --ViroPharma Incorporated (VPHM) reported today its financial results for the third quarter ended September 30, 2012. Since June 30, 2012, we: Net sales were $91 million for the third quarter ended September 30, 2012, as compared to $143 million in the same three months of 2011. The decrease was the direct result of the impact of generic oral vancomycin entries into the market. Regarding Cinryze, during the quarter the U.S. channel inventory increased by approximately $2 million. Net sales were $321 million for the nine months ended September 30, 2012, as compared to $399 million in the comparative period of 2011. "The third quarter of 2012 was a period of tremendous fundamental execution for ViroPharma," stated Vincent Milano, ViroPharma's chief executive officer. "Despite several early challenges in 2012, the progress and achievements that have been made across our entire organization in the first nine months have rapidly shifted the focus towards the promise of what ViroPharma can deliver for both our patients and our shareholders alike in the years ahead. We are seeing remarkable growth with Cinryze here in the United States, our product launches in Europe are beginning to gain ground and the … Continue reading →

EXTON, Pa., Oct. 22, 2012 /PRNewswire/ --ViroPharma Incorporated (VPHM) today announced that Health Canada has granted a Notice of Compliance (NOC) and approved a New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]). Approval of Cinryze was granted for routine prevention of angioedema attacks in adult and adolescents with hereditary angioedema (HAE). Until now, there have been no approved plasma derived C1 inhibitor therapies for routine prevention of HAE attacks in Canada. ViroPharma's Canadian headquarters are located in Oakville, Ontario. We anticipate Cinryze to be commercially available in Canada as early as the second quarter of 2013. "Hereditary angioedema is a complex and life threatening disease that must be managed carefully by physicians," said Dr. Tom Bowen, clinical professor of medicine and pediatrics at the University of Calgary. "The approval of Cinryze to help prevent HAE attacks provides an essential addition to the patient care arsenal of physicians across Canada. Disease management options that provide choices for patients for both treatment and prevention of hereditary angioedema can help patients reach their own personal health and wellness goals." "It is important to have a number of disease management options available for those living with hereditary angioedema," said Della Cogar, founder, HAE … Continue reading →

Featured Article Main Category: Epilepsy Also Included In: Regulatory Affairs / Drug Approvals;Neurology / Neuroscience Article Date: 24 Oct 2012 - 3:00 PDT Current ratings for: Epilepsy Drug Fycompa Receives FDA Approval 3 (2 votes) 3 (1 votes) The drug, made by Eisai Inc, the US arm of the Japanese global pharma company, is already approved for use in Iceland, Norway and the European Commission on behalf of its 27 sovereign member states. Epilepsy is a spectrum of brain disorders, ranging from severe, life-threatening and disabling, to more benign. It arises because of abnormal or excessive activity of nerve cells in the brain, which can cause seizures that give rise to symptoms ranging from strange sensations, unusual behavior, repetitive limb movements (spasms), to generalized convulsions with loss of consciousness. Partial seizures are the most common type of seizure, affecting some 60% of people with the condition. They affect only a limited or localized part of the brain, but can spread to other parts. Russell Katz, director of the FDA's Division of Neurology Products in the agency's Center for Drug Evaluation and Research, emphasizes this point in a press statement, adding: "It is important to have a variety of treatment options … Continue reading →

HORSHAM, Pa., Oct. 18, 2012 /PRNewswire/ --A panel of parents who became patient advocates after their children were diagnosed with rare diseases will discuss their struggles and successes in navigating the drug development process on Monday at a Washington, D.C., conference sponsored by DIA and the National Organization for Rare Disorders (NORD). The work carried out by these parents through rare disease associations can be one of the most important factors in getting lifesaving help for their children. For many parents, the news that their child has a rare disease has changed the course of their lives, including their leaving other careers to work full time to advance the development of therapies to treat severe illnesses that may affect as few as 500 people in the United States. Five of these parents and one patient will speak at the 2012 U.S. Conference on Rare Diseases and Orphan Products. "People are going along living their lives and then learn their child has a rare disease. These parents are diving into a world unknown to them to navigate the complicated path to find a treatment," said Peter L. Saltonstall, NORD president and CEO. "We see it over and over again. The result … Continue reading →

Question: I am a 26-year-old black woman. All through high school, I begged my mother to let me get my ears pierced. She said to wait until I graduated from college and was on my own. I did. On each ear, the piercing left a huge scar. The doctor called it a keloid. What are keloids and what is their treatment? Answer: Keloids are scars that form far too much scar tissue. The result is an unsightly, overgrown and sometimes disfiguring scar. Scars from surgery, from an inadvertent cut and from procedures as innocuous as ear piercing can become keloids. People of Asian and African descent are particularly vulnerable to developing such scars. I don't want to discourage you, but keloid treatment often involves a recurrence of a keloid scar. Plastic surgeons and dermatologists are the doctors to consult for possible correction. I'll give you some examples of how keloids are treated: One way is injecting them with potent cortisone drugs, such as triamcinolone. A good response occurs in 70 percent of patients, but the recurrence rate is also high. Excision of the scar followed by triamcinolone injections into the newly healing tissues is another method. Silicone gel sheeting can … Continue reading →